May 20, 2019
Search
168 Result(s)
June 14, 2022
Boehringer Ingelheim and CarthroniX announce partnership to pursue small molecule therapeutics in canine oncology
Human Health Partnering Interests
Oncology and Cancer Immunology
Science Focus
Oncology and Cancer Immunology
Across Cancer Types
Immuno-Oncology
Investing in the next wave of Immuno-Oncology
Pets
A brighter future for pets with cancer
Our R&D team's efforts toward finding new cancer treatments for pets
Across Cancer Types
Targeting Tumor Stroma: The Therapeutic White Space in Oncology
Find out more about our pioneering science in stromal biology and its potential to change the face of cancer treatment.
November 22, 2023
Boehringer Ingelheim expands immuno-oncology portfolio with the acquisition of bacterial cancer therapy specialist T3 Pharma
Clinical Collaborations
Collaboration at our Heart
Our collaborative approach is grounded in mutual trust, shared goals and a passion for leading science.
Across Cancer Types
How scientific congresses drive patient benefit
What is happening behind the doors of congress centers? How do patients benefit from the participation of pharmaceutical representatives? Let’s shed some light.
Science Focus
Retinal Health
Science Stories
Protein Degraders: Changing the Game in Cancer Drug Discovery
Boehringer Ingelheim scientists and their partners are exploring how protein degraders could bring so-called undruggable cancer targets within reach
Article
“We do everything we can to help”
Interview with Dr Mehdi Shahidi, Chief Medical Officer and Head of the Corporate Division Medicine at Boehringer Ingelheim
Empowering Patients
Social Support
Hear the perspectives of people living with cancer on the importance of social support.
Science Stories
SIRPα: A New Chapter in Cancer Immunology Research
Boehringer Ingelheim scientists are exploring a research path scientifically less travelled by investigating a new target in the innate immune system
Grass Roots
About Our Innovation Prize
Find out more about how we’re providing valuable resources to life-science innovators to enable new and emerging science
Human Health Partnering Interests
Retinal Health
Retinal Diseases
Our Vision for Retinal Health
Visual impairment and blindness have a profound and devastating impact on the lives of the affected person, their families and society as a whole.
Human Health Partnering Interests
Technologies
Science Stories
Innovation in Medicinal Chemistry: Unlocking Unsolved Diseases
From AI to PROTACs, Darryl McConnell and Jürgen Mack explain how our teams leverage cutting-edge approaches aiming to bring ‘undruggable’ targets within reach.
Cancer
Brightline-1 trial launch in rare sarcoma
Find out more from Mehdi Lahmar, Clinical Program Leader for Oncology, about our commitment to patients with Dedifferentiated Liposarcoma (DDLPS).
Cancer
Why cancer care is personal for us
Find out more about Boehringer Ingelheim’s generational commitment to transforming cancer care.
Lung Cancer
Our goal of transforming DLL3-positive carcinomas
Our progress in developing a potential targeted immunotherapy for DLL3-positive small cell lung cancer and neuroendocrine carcinomas.
March 16, 2020
New uncommon EGFR mutations database published featuring clinical outcomes of NSCLC patients treated with afatinib
Science Stories
Targeting MDM2-p53 in cancer: The story of brigimadlin
Our perseverance and passion for science led to the discovery of brigimadlin, our MDM2-p53 antagonist. It is being clinically investigated as a potential treatment for dedifferentiated liposarcoma, a rare cancer with significant unmet needs.